As shown in Fig. 5A, CPX or BTZ treatment increased p-p65 levels in GBM cells, whereas p65 expression was unchanged, and the NF-κB-signaling inhibitory protein, IκBα, decreased. The gene discussed is NFKB1; the disease is glioblastoma.